Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 4012-4019

  Vocat, Anthony ^a   Hartkoorn, Ruben C ^a   Lechartier, Benoit ^a,b   Zhang, Ming ^a,c   Dhar, Neeraj ^a   Cole, Stewart T ^a   Sala, Claudia ^a  

^a EPFL   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; AMINOSALICYLIC ACID; AU 1235; BEDAQUILINE; BTZ 043; CLOFAZIMINE; ETHAMBUTOL; GLUCOSE; ISONIAZID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PRETOMANID; PYRAZINAMIDE; RIFAMPICIN; RIFAMYCIN; RIFAMYCIN DERIVATIVE; SUTEZOLID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; ADAMANTANE; ETHYLENEDIAMINE DERIVATIVE; N-GERANYL-N'-(2-ADAMANTYL)ETHANE-1,2-DIAMINE; OXAZINE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PNU-100480; QUINOLINE DERIVATIVE; RESAZURIN; XANTHENE DERIVATIVE;

ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BIOLUMINESCENCE; CARBON SOURCE; CFU COUNTING; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; IN VITRO STUDY; LUCIFERASE ASSAY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPERON; OPTICAL DENSITY; PHOTORHABDUS LUMINESCENS; PRIORITY JOURNAL; RESAZURIN ASSAY; ANALOGS AND DERIVATIVES; BACTERIAL COUNT; BACTERIAL GENE; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; LUMINESCENCE; METABOLISM; MICROBIAL SENSITIVITY TEST; PHOTORHABDUS; PROCEDURES;

ADAMANTANE; ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; DIARYLQUINOLINES; DRUG DISCOVERY; ETHYLENEDIAMINES; GENES, BACTERIAL; LUMINESCENCE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OXAZINES; OXAZOLIDINONES; PHOTORHABDUS; PYRAZINAMIDE; RIFAMYCINS; XANTHENES;

EID: 84931275152     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00528-15     Document Type: Article

References (36)

1. World Health Organization. 2014. Tuberculosis fact sheet. World Health Organization, Geneva, Switzerland.
2. Boshoff HI, Barry CE, III. 2005. Tuberculosis: metabolism and respiration in the absence of growth. Nat Rev Microbiol 3:70-80. http://dx.doi.org/10.1038/nrmicro1065.
3. Gomez JE, McKinney JD. 2004. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 84:29-44. http://dx.doi.org/10.1016/j.tube.2003.08.003.
4. Sala C, Dhar N, Hartkoorn RC, Zhang M, Ha YH, Schneider P, Cole ST. 2010. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 54:4150-4158. http://dx.doi.org/10.1128/AAC.00821-10.
5. Zhang M, Sala C, Dhar N, Vocat A, Sambandamurthy VK, Sharma S, Marriner G, Balasubramanian V, Cole ST. 2014. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:3217-3223. http://dx.doi.org/10.1128/AAC.02410-14.
6. Zhang M, Sala C, Hartkoorn RC, Dhar N, Mendoza-Losana A, Cole ST. 2012. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob Agents Chemother 56: 5782-5789. http://dx.doi.org/10.1128/AAC.01125-12.
7. Andreu N, Fletcher T, Krishnan N, Wiles S, Robertson BD. 2012. Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence. J Antimicrob Chemother 67:404-414. http://dx.doi.org/10.1093/jac/dkr472.
8. Andreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, Ripoll J, Parish T, Bancroft GJ, Schaible U, Robertson BD, Wiles S. 2010. Optimisation of bioluminescent reporters for use with mycobacteria. PLoS One 5:e10777. http://dx.doi.org/10.1371/journal.pone.0010777.
9. Andreu N, Zelmer A, Sampson SL, Ikeh M, Bancroft GJ, Schaible UE, Wiles S, Robertson BD. 2013. Rapid in vivo assessment of drug efficacy against Mycobacterium tuberculosis using an improved firefly luciferase. J Antimicrob Chemother 68:2118-2127. http://dx.doi.org/10.1093/jac/dkt155.
10. Andrew PW, Roberts IS. 1993. Construction of a bioluminescent mycobacterium and its use for assay of antimycobacterial agents. J Clin Microbiol 31:2251-2254.
11. Arain TM, Resconi AE, Hickey MJ, Stover CK. 1996. Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. Antimicrob Agents Chemother 40:1536-1541.
12. Cooksey RC, Crawford JT, Jacobs WR, Jr, Shinnick TM. 1993. A rapid method for screening antimicrobial agents for activities against a strain of Mycobacterium tuberculosis expressing firefly luciferase. Antimicrob Agents Chemother 37:1348-1352. http://dx.doi.org/10.1128/AAC.37.6.1348.
13. Deb DK, Srivastava KK, Srivastava R, Srivastava BS. 2000. Bioluminescent Mycobacterium aurum expressing firefly luciferase for rapid and high throughput screening of antimycobacterial drugs in vitro and in infected macrophages. Biochem Biophys Res Commun 279:457-461. http://dx.doi.org/10.1006/bbrc.2000.3957.
14. Heuts F, Carow B, Wigzell H, Rottenberg ME. 2009. Use of non-invasive bioluminescent imaging to assess mycobacterial dissemination in mice, treatment with bactericidal drugs and protective immunity. Microbes Infect 11:1114-1121. http://dx.doi.org/10.1016/j.micinf.2009.08.005.
15. Hickey MJ, Arain TM, Shawar RM, Humble DJ, Langhorne MH, Morgenroth JN, Stover CK. 1996. Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice. Antimicrob Agents Chemother 40: 400-407.
16. Snewin VA, Gares MP, Gaora PO, Hasan Z, Brown IN, Young DB. 1999. Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect Immun 67:4586-4593.
17. Zhang T, Li SY, Nuermberger EL. 2012. Autoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy. PLoS One 7:e29774. http://dx.doi.org/10.1371/journal.pone.0029774.
18. Sharma S, Gelman E, Narayan C, Bhattacharjee D, Achar V, Humnabadkar V, Balasubramanian V, Ramachandran V, Dhar N, Dinesh N. 2014. Simple and rapid method to determine antimycobacterial potency of compounds by using autoluminescent Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:5801-5808. http://dx.doi.org/10.1128/AAC.03205-14.
19. Parish T, Stoker NG. 1998. Electroporation of mycobacteria. Methods Mol Biol 101:129-144.
20. Zhang JH, Chung TD, Oldenburg KR. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67-73. http://dx.doi.org/10.1177/108705719900400206.
21. Makarov V, Manina G, Mikusova K, Mollmann U, Ryabova O, Saint-Joanis B, Dhar N, Pasca MR, Buroni S, Lucarelli AP, Milano A, De Rossi E, Belanova M, Bobovska A, Dianiskova P, Kordulakova J, Sala C, Fullam E, Schneider P, McKinney JD, Brodin P, Christophe T, Waddell S, Butcher P, Albrethsen J, Rosenkrands I, Brosch R, Nandi V, Bharath S, Gaonkar S, Shandil RK, Balasubramanian V, Balganesh T, Tyagi S, Grosset J, Riccardi G, Cole ST. 2009. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324:801-804. http://dx.doi.org/10.1126/science.1171583.
22. Chakraborty S, Gruber T, Barry CE, III, Boshoff HI, Rhee KY. 2013. para-Aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science 339:88-91. http://dx.doi.org/10.1126/science.1228980.
23. Zheng J, Rubin EJ, Bifani P, Mathys V, Lim V, Au M, Jang J, Nam J, Dick T, Walker JR, Pethe K, Camacho LR. 2013. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. J Biol Chem 288:23447-23456. http://dx.doi.org/10.1074/jbc.M113.475798.
24. Belanger AE, Besra GS, Ford ME, Mikusova K, Belisle JT, Brennan PJ, Inamine JM. 1996. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci USA93:11919-11924. http://dx.doi.org/10.1073/pnas.93.21.11919.
25. Grzegorzewicz AE, Pham H, Gundi VA, Scherman MS, North EJ, Hess T, Jones V, Gruppo V, Born SE, Kordulakova J, Chavadi SS, Morisseau C, Lenaerts AJ, Lee RE, McNeil MR, Jackson M. 2012. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol 8:334-341. http://dx.doi.org/10.1038/nchembio.794.
26. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966. http://dx.doi.org/10.1038/35016103.
27. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. http://dx.doi.org/10.1126/science.1106753.
28. Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, Fischer E, Barnes SW, Walker JR, Alland D, Barry CE, III, Boshoff HI. 2012. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56:1797-1809. http://dx.doi.org/10.1128/AAC.05708-11.
29. Shaw KJ, Barbachyn MR. 2011. The oxazolidinones: past, present, and future. Ann N Y Acad Sci 1241:48-70. http://dx.doi.org/10.1111/j.1749-6632.2011.06330.x.
30. Craney A, Hohenauer T, Xu Y, Navani NK, Li Y, Nodwell J. 2007. A synthetic luxCDABE gene cluster optimized for expression in high-GC bacteria. Nucleic Acids Res 35:e46. http://dx.doi.org/10.1093/nar/gkm086.
31. Koga K, Harada T, Shimizu H, Tanaka K. 2005. Bacterial luciferase activity and the intracellular redox pool in Escherichia coli. Mol Genet Genomics 274:180-188. http://dx.doi.org/10.1007/s00438-005-0008-5.
32. Munoz-Elias EJ, McKinney JD. 2005. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat Med 11:638-644. http://dx.doi.org/10.1038/nm1252.
33. Russell DG, VanderVen BC, Lee W, Abramovitch RB, Kim MJ, Homolka S, Niemann S, Rohde KH. 2010. Mycobacterium tuberculosis wears what it eats. Cell Host Microbe 8:68-76. http://dx.doi.org/10.1016/j.chom.2010.06.002.
34. Pethe K, Sequeira PC, Agarwalla S, Rhee K, Kuhen K, Phong WY, Patel V, Beer D, Walker JR, Duraiswamy J, Jiricek J, Keller TH, Chatterjee A, Tan MP, Ujjini M, Rao SP, Camacho L, Bifani P, Mak PA, Ma I, Barnes SW, Chen Z, Plouffe D, Thayalan P, Ng SH, Au M, Lee BH, Tan BH, Ravindran S, Nanjundappa M, Lin X, Goh A, Lakshminarayana SB, Shoen C, Cynamon M, Kreiswirth B, Dartois V, Peters EC, Glynne R, Brenner S, Dick T. 2010. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun 1:57. http://dx.doi.org/10.1038/ncomms1060.
35. Li K, Schurig-Briccio LA, Feng X, Upadhyay A, Pujari V, Lechartier B, Fontes FL, Yang H, Rao G, Zhu W, Gulati A, No JH, Cintra G, Bogue S, Liu YL, Molohon K, Orlean P, Mitchell DA, Freitas-Junior L, Ren F, Sun H, Jiang T, Li Y, Guo RT, Cole ST, Gennis RB, Crick DC, Oldfield E. 2014. Multitarget drug discovery for tuberculosis and other infectious diseases. J Med Chem 57:3126-3139. http://dx.doi.org/10.1021/jm500131s.
36. + bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Sci Transl Med 5:170ra13. http://dx.doi.org/10.1126/scitranslmed.3004912.